Home
Search
Study Topics
Glossary
|
Study 17 of 872 for search of: | "Paraproteinemias" |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsors and Collaborators: |
Hadassah Medical Organization Vaxil Therapeutics Ltd. |
---|---|
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00162500 |
Rationale:
ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the majority of the target population.
Purpose:
The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA).
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma Tumors |
Biological: Peptide Vaccine (MUC-1) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | A Novel Vaccine for the Treatment of MUC1-Expressing Tumor Malignancies |
Estimated Enrollment: | 15 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All patients must have a histological or cytological diagnosis of metastatic disease expressing the MUC-1. Patients must have metastatic disease and have failed at least one regimen of standard based chemotherapy for metastatic disease such as:
Exclusion Criteria:
Contact: Shimon Slavin, MD | +972-2-6776561 | slavin@hadassah.org.il |
Contact: Lior Carmon, PHD, MBA | +972-3-6491190 | mkcarmon@inter.net.il |
Israel | |
Hadassah Medical Organization | |
Jerusalem, Israel, 91120 |
Principal Investigator: | Shimon Slavin, MD | Hadassah Medical Organization |
Study ID Numbers: | 191203-HMO-CTIL |
Study First Received: | September 11, 2005 |
Last Updated: | January 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00162500 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Metastatic solid tumors |
Immunoproliferative Disorders Hemorrhagic Disorders Multiple myeloma Hematologic Diseases Blood Protein Disorders Blood Coagulation Disorders |
Vascular Diseases Paraproteinemias Lymphoproliferative Disorders Hemostatic Disorders Neoplasms, Plasma Cell Multiple Myeloma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases Cardiovascular Diseases |